TRP-PK1
TRP-PK1 is a polypeptide. TRP-PK1 can be derived from the fourth transmembrane segment of TRPV4. TRP-PK1 can insert into the phospholipid bilayer. TRP-PK1 self-assembles to form K+-permeable channels, mediates K+ flux, hyperpolarizes the membrane potential of vascular smooth muscle, relaxes agonist-induced vasoconstriction, and lowers mean arterial pressure. TRP-PK1 enhances the tumor-targeting capability of cell membrane vesicles and displays Angiopep-2 (HY-P2341) on the surface of engineered vesicles. TRP-PK1 can be used for research on glioblastoma multiforme, head and neck cancer, and hypertension.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 分子式: C132H199N29O29S2
- 分子量:2720.30
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
生物活性
製品説明
IC50 & Target
[1]|
TRPV4 |
体外実験
ANG-TRP-PK1@EAVs (25-200 μg; 24-48 h) exhibit no significant cytotoxicity in U87MG, U251, or L02 cells[1].
ANG-TRP-PK1@EAVs demonstrate specific targeting to U87MG glioma cells[1].
TRP-PK1 modification alone facilitates the uptake of RBCVs by HN4 cells[2].
TRP-PK1 (500 nM) self-assembles into cation-permeable ion channels with a conductance of 51.5 pS in giant liposome membranes, as measured by patch-clamp single-channel recording[3].
TRP-PK1 (5 μM) effectively mediates K+ flow into liposomes, as demonstrated by increased intravesicular PBFI fluorescence[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:U87MG, U251, L02
-
Concentration:25, 50, 100, 200 μg (24 h); 50 μg (24 and 48 h)
-
Incubation Time:24 h; 48 h
-
Result:Showed no cytotoxicity in U87MG, U251, or L02 cells at concentrations of 25, 50, 100, and 200 μg for 24 h.
Showed no significant cell toxicity in U87MG, U251, and L02 cells at 50 μg for 48 h.
体内実験
TRP-PK1 (1 mg/25 g; intravenous injection; single bolus injection; 10 min) significantly reduces mean arterial pressure in anesthetized mice[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c nude mice (female, approximately 7 weeks old, HN4 cell-derived xenograft model)[2]
-
Dosage:2 mg/kg
-
Administration:i.v.; once every three days
-
Result:Showed tumor sizes comparable to the PBS control group.
Did not effectively reduce PCNA expression in tumor tissues compared to the control.
Showed no significant pathological changes in major organs including heart, liver, spleen, lungs, and kidneys.
-
Animal Model:C57 mice (male, 4-6 weeks old, approximately 25 g)[3]
-
Dosage:1 mg/25 g
-
Administration:i.v.; single bolus injection; 10 min
-
Result:Decreased mean arterial pressure (MAP) by approximately -4 mmHg compared to approximately -0.7 mmHg with DMSO control (n = 5).
化学情報
-
分子量 2720.30
-
分子式 C132H199N29O29S2
-
配列
Ala-Tyr-Leu-Ala-Val-Met-Val-Phe-Ala-Leu-Val-Leu-Gly-Trp-Met-Asn-Ala-Leu-Tyr-Phe-Thr-Arg-Gly-Leu
-
シーケンスの短縮
AYLAVMVFALVLGWMNALYFTRGL
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
プロトコル
-
Fluorescent plasma-membrane potential dye assay
Fluorescent plasma-membrane potential dye assays measure changes in cell membrane potential using voltage-sensitive dyes whose fluorescence changes when cells depolarize or hyperpolarize. Anionic bis-oxonol dyes such as DiBAC4(3) enter depolarized cells more readily and show increased fluorescence after intracellular binding, while hyperpolarization reduces dye accumulation and fluorescence. FMP/FLIPR membrane-potential dyes are used for faster, homogeneous microplate assays of ion-channel or receptor-mediated membrane-potential changes.
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
純度とドキュメンテーション
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)